Review Shows Bevacizumab Has Gained Momentum for Mesothelioma...
The VEGF inhibitor is now part of the standard treatment for pleural mesothelioma in France and a recognized first-line option for American clinicians.(PRWeb November 06, 2017)Read the full story at http://www.prweb.com/releases/2017/11/prweb14884392.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 6, 2017 Category: Pharmaceuticals Source Type: news

Taxpayers pay twice for crucial drugs like Avastin | Letters
Big pharma companies are charging over the odds for medicines developed with public funding, writeHeidi Chow andTabitha HaIt is shocking, but not surprising, that big drugs companies are threatening to sue the NHS for using cheaper versions of drugs that could save people from going blind (Drug firms trying to stop cheap eye treatment on NHS, 1 November). Another part of this story is that the two medicines in question – Lucentis (known generically as ranibizumab) and Avastin (bevacizumab) are based on the groundbreaking discovery of monoclonal antibodies, whichwere developed with UK public funding.The NHS itself funded ...
Source: Guardian Unlimited Science - November 5, 2017 Category: Science Authors: Letters Tags: NHS Drugs Medical research Science Health Society Pharmaceuticals industry Business Blindness and visual impairment Disability Source Type: news

Policy and regulation stand in the way of NHS use of unlicensed eye injection drug with potential to save millions of pounds
Eye injection drugs recommended by NICE cost the NHS up to £ 447 million annually, but could be replaced by an unlicensed drug, bevacizumab, costing as much as ten times less. Use of the two licensed drugs, ranibizumab and aflibercept, has increased three-fold over the last five years, with some parts of England treating five times as many patients as others. (Source: University of Bristol news)
Source: University of Bristol news - November 1, 2017 Category: Universities & Medical Training Tags: Health, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences, Population Health Sciences; Press Release Source Type: news

Health chiefs facing legal fight over cheaper eye drug
Prescribing Avastin will save the NHS "millions of pounds", health bosses say. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 1, 2017 Category: Consumer Health News Source Type: news

Doctors face legal action over use of unlicensed eye drug
They want to prescribe Avastin for wet AMD rather than costlier alternatives Related items fromOnMedica UK patients losing out in access to cancer drugs Drug and Therapeutics Update UK ‘inadequate’ at regulating off-label drugs GMC steps into eye drug row Novartis accused of attempt to derail eye drug trials (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 1, 2017 Category: UK Health Source Type: news

FDA accepts Roche ’s supplemental Biologics License Application for Avastin as a front-line treatment for women with advanced ovarian cancer
Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company ' s supplemental Biologics License Application (sBLA) for Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone, for the front-line treatment of women with advanced ovarian cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - October 26, 2017 Category: Pharmaceuticals Source Type: news

Mvasi (Bevacizumab-awwb Solution for Intravenous Infusion) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 27, 2017 Category: Drugs & Pharmacology Source Type: news

Laser May Be Safer Than Bevacizumab in Babies With Acute-phase ROP Laser May Be Safer Than Bevacizumab in Babies With Acute-phase ROP
Babies with acute-phase retinopathy of prematurity (ROP) who are treated with bevacizumab have more long-term eye problems than babies treated with laser, according to a new randomized controlled trial done in Italy.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 18, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Amgen and Allergan ’s anti-cancer biosimilar Mvasi receives FDA approval
The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 17, 2017 Category: Pharmaceuticals Source Type: news

FDA has approved biosimilar of Roche's Avastin
Amgen Inc. AMGN, -1.37% and Allergan AGN, -1.08% said Thursday that the Food and Drug Administration has approved their biosimilar version of Roche's Avastin for five types of cancer.09/15/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 15, 2017 Category: Urology & Nephrology Source Type: news

Mvasi Is First Biosimilar Drug Approved for Cancer
Similar to Avastin (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - September 15, 2017 Category: Cancer & Oncology Source Type: news

FDA Approves First Biosimilar Drug for Cancer
Mvasi (bevacizumab - awwb) is biosimilar to Avastin (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Gynecology, Internal Medicine, Nephrology, Oncology, Pharmacy, Pulmonology, Institutional, Source Type: news

Mvasi Is First Biosimilar Drug Approved for Cancer
Similar to Avastin (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 14, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
September 14, 2017 -- The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 14, 2017 Category: Drugs & Pharmacology Source Type: news